All In Biotech

Drug Trial Radar · NCT04770207

Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs

Intra-tumor Injection of Drug-eluting Microspheres Loading With Chemodrug Plus Checkpoint Inhibitors and/or IL2 for Treatment of Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 1, 2020

Primary completion

Nov 1, 2029

Study completion Nov 1, 2035

Sponsor

Lead sponsor
Second Affiliated Hospital of Guangzhou Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To study the safety and clinical effect of injection of drug-eluting microspheres with multiple chemodrug and/or protein drugs into advanced solid tumors.

Conditions

  • Hepatocellular Carcinoma
  • Solid Tumor, Adult

Interventions

  • Injection of drug-eluting microspheres with multiple drugs into solid tumorsDrug

    Under the guidance of CT, puncture fine needle was used to inject drug-eluting microspheres loading with multiple drugs into the tumor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessing safety and treatment efficacy on intra-tumor injection of DEB for advanced tumorsTime frame: up to 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.